Could a simple blood test curb antibiotic overuse in sick kids?
NCT ID NCT05350813
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether using a blood marker called procalcitonin (PCT) to guide antibiotic decisions can safely shorten treatment duration in children with bacterial infections in intensive care. About 296 children will be randomly assigned to either PCT-guided care or standard practice, and their total antibiotic use will be compared over 28 days. The goal is to see if this approach reduces unnecessary antibiotic exposure without compromising recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A procalcitonin (PCT)-guided algorithm to determine when to stop antibiotics, compared with standard care based on guidelines.
- What this could lead to
- If effective, this approach could reduce unnecessary antibiotic exposure in hospitalized children, lowering side effects and the risk of antibiotic resistance.
- What could go wrong
- The trial is relatively small and open-label, which may introduce bias. The algorithm may not be suitable for all infections, and there is a risk of undertreatment if it guides stopping antibiotics too early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP
ACTIVE_NOT_RECRUITINGParis, France
-
CHU Amiens Picardie
ACTIVE_NOT_RECRUITINGAmiens, France
-
CHU La Réunion
RECRUITINGSaint-Denis, France
-
CHU de Bordeaux
ACTIVE_NOT_RECRUITINGBordeaux, France
-
CHU de Clermont Ferrand
RECRUITINGClermont-Ferrand, France
-
CHU de NANTES
RECRUITINGNantes, France
-
University Hospital of Lille
TERMINATEDLille, France
-
University Hospital of Toulouse
RECRUITINGToulouse, 31100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can smarter antibiotic choices curb superbugs in liver disease?
- New bedside test could help doctors fine-tune antibiotics in real time
- Vaccine Follow-Up: how long does protection last in babies?
- New antibiotic vabomere tested in kids for first time
- Could personalized antibiotic dosing save lives in liver cirrhosis?